MedTrace Logo

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

NCT04060641 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-02-16

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness of a multi-gene panel to determine which subjects are likely to respond to renal denervation therapy with Medtronic's Symplicity Spyral™ multi-electrode renal denervation system.

Conditions

Interventions

GENETIC

Geneticure for RDN Genetic Panel

This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation

Sponsors & Collaborators

  • Geneticure, LLC

    lead INDUSTRY

Principal Investigators

  • Eric M Snyder · Geneticure, LLC

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2022-05-01
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060641 on ClinicalTrials.gov